Alzheimer’s Research Corporation Offers Treatment Options, Picture a World without Memories
Alzheimer’s disease steals our memories and causes great anguish for patients and their families. Memories define us. Without them, who are we to ourselves and to our loved ones? The Alzheimer’s Research Corporation (ARC) founded in 1992 is committed to providing treatment alternatives for those individuals exhibiting signs of memory loss and possible/probable dementia.
For almost 20 years, ARC has conducted over 80 clinical trials mainly in the area of Alzheimer’s disease. ARC, an affiliate of Mid Atlantic Geriatric Association (MAGA) is located within the Manchester MAGA office. The practice location is unique in that it is part of a medical practice where medical, social and legal guidance is available in one location. Patients and caregivers have access to the healthcare team as needed.
Dr. Joshua Shua-Haim serves as the Principal Investigator for all clinical trials conducted. His expertise in the treatment of Alzheimer’s disease is without comparison. His research team consists of highly skilled professionals who collectively have over 50 years of research experience.
All trials are conducted with strict adherence to the Code of Federal Regulations and utilize Good Clinical Practices. The site has been audited by the Food & Drug Association (FDA) in 2000 and 2003. No contingencies were imposed as a result of these inspections. The site is recognized as star performers by many in the pharmaceutical industry.
If you or a loved one have been diagnosed with mild, moderate or advanced Alzheimer’s disease and are seeking new or adjuvant therapies, please visit the “Enrolling Studies” section to see what studies are currently enrolling at our site.